Cargando…

COVID‐19 and plasma cells: Is there long‐lived protection?

Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long‐lived plasma cells (LLPC) are the mainstay...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Doan C., Lamothe, Pedro A., Woodruff, Matthew C., Saini, Ankur S., Faliti, Caterina E., Sanz, Ignacio, Lee, Frances Eun‐Hyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350162/
https://www.ncbi.nlm.nih.gov/pubmed/35801537
http://dx.doi.org/10.1111/imr.13115
_version_ 1784762187290509312
author Nguyen, Doan C.
Lamothe, Pedro A.
Woodruff, Matthew C.
Saini, Ankur S.
Faliti, Caterina E.
Sanz, Ignacio
Lee, Frances Eun‐Hyung
author_facet Nguyen, Doan C.
Lamothe, Pedro A.
Woodruff, Matthew C.
Saini, Ankur S.
Faliti, Caterina E.
Sanz, Ignacio
Lee, Frances Eun‐Hyung
author_sort Nguyen, Doan C.
collection PubMed
description Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long‐lived plasma cells (LLPC) are the mainstay of most effective vaccines. However, ending the pandemic has been hampered by the lack of long‐lived immunity after infection or vaccination. Although immunizations offer protection from severe disease and hospitalization, breakthrough infections still occur, most likely due to new mutant viruses and the overall decline of neutralizing antibodies after 6 months. Here, we review the current knowledge of B cells, from extrafollicular to memory populations, with a focus on distinct plasma cell subsets, such as early‐minted blood antibody‐secreting cells and the bone marrow LLPC, and how these humoral compartments contribute to protection after SARS‐CoV‐2 infection and immunization.
format Online
Article
Text
id pubmed-9350162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93501622022-08-04 COVID‐19 and plasma cells: Is there long‐lived protection? Nguyen, Doan C. Lamothe, Pedro A. Woodruff, Matthew C. Saini, Ankur S. Faliti, Caterina E. Sanz, Ignacio Lee, Frances Eun‐Hyung Immunol Rev Invited Reviews Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long‐lived plasma cells (LLPC) are the mainstay of most effective vaccines. However, ending the pandemic has been hampered by the lack of long‐lived immunity after infection or vaccination. Although immunizations offer protection from severe disease and hospitalization, breakthrough infections still occur, most likely due to new mutant viruses and the overall decline of neutralizing antibodies after 6 months. Here, we review the current knowledge of B cells, from extrafollicular to memory populations, with a focus on distinct plasma cell subsets, such as early‐minted blood antibody‐secreting cells and the bone marrow LLPC, and how these humoral compartments contribute to protection after SARS‐CoV‐2 infection and immunization. John Wiley and Sons Inc. 2022-07-08 2022-08 /pmc/articles/PMC9350162/ /pubmed/35801537 http://dx.doi.org/10.1111/imr.13115 Text en © 2022 The Authors. Immunological Reviews published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Invited Reviews
Nguyen, Doan C.
Lamothe, Pedro A.
Woodruff, Matthew C.
Saini, Ankur S.
Faliti, Caterina E.
Sanz, Ignacio
Lee, Frances Eun‐Hyung
COVID‐19 and plasma cells: Is there long‐lived protection?
title COVID‐19 and plasma cells: Is there long‐lived protection?
title_full COVID‐19 and plasma cells: Is there long‐lived protection?
title_fullStr COVID‐19 and plasma cells: Is there long‐lived protection?
title_full_unstemmed COVID‐19 and plasma cells: Is there long‐lived protection?
title_short COVID‐19 and plasma cells: Is there long‐lived protection?
title_sort covid‐19 and plasma cells: is there long‐lived protection?
topic Invited Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350162/
https://www.ncbi.nlm.nih.gov/pubmed/35801537
http://dx.doi.org/10.1111/imr.13115
work_keys_str_mv AT nguyendoanc covid19andplasmacellsistherelonglivedprotection
AT lamothepedroa covid19andplasmacellsistherelonglivedprotection
AT woodruffmatthewc covid19andplasmacellsistherelonglivedprotection
AT sainiankurs covid19andplasmacellsistherelonglivedprotection
AT faliticaterinae covid19andplasmacellsistherelonglivedprotection
AT sanzignacio covid19andplasmacellsistherelonglivedprotection
AT leefranceseunhyung covid19andplasmacellsistherelonglivedprotection